Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 1, 2003. The report details specific share repurchase activities executed in November 2003 under authority granted by shareholders at the Annual General Meeting on May 19, 2003.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to share buyback transactions:
- November 3, 2003: Purchased 500,000 Ordinary 25 pence shares for cancellation at 1,273.86092 pence per share.
- November 4, 2003: Purchased 750,000 Ordinary 25 pence shares for cancellation at 1,268.28 pence per share.
Material Changes
The filing does not report material changes in operating results or financial position compared to prior periods. The primary activity reported is the reduction of outstanding share capital through the cancellation of 1,250,000 shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, risk factors, or contingencies. It is strictly a notification of completed share repurchases.
Key Facts for Investor Verification
- Verify the total number of shares repurchased and cancelled (1,250,000) against the company's remaining share capital.
- Confirm the average price paid per share (approximately 1,271 pence) relative to the market price at the time of execution.
- Check subsequent filings to determine if the remaining authority from the May 2003 shareholder meeting was utilized.